Literature DB >> 18927587

Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression.

J Du1, X Liang, Y Liu, Z Qu, L Gao, L Han, S Liu, M Cui, Y Shi, Z Zhang, L Yu, L Cao, C Ma, L Zhang, Y Chen, W Sun.   

Abstract

Hepatitis B virus (HBV) causes chronic hepatitis in hundreds of millions of people worldwide, which can eventually lead to hepatocellular carcinoma (HCC). The molecular mechanisms underlying HBV persistence are not well understood. TRAIL, the TNF-related apoptosis-inducing ligand, has recently been implicated in hepatocyte death during HBV infection. We report here that the HBV core protein (HBc) is a potent inhibitor of TRAIL-induced apoptosis. Overexpressing HBc significantly decreased TRAIL-induced apoptosis of human hepatoma cells, whereas knocking-down HBc expression in hepatoma cells transfected with HBV genome enhanced it. When present in the same cell, HBc blocked the pro-apoptotic effect of the HBV X protein (HBx). The resistance of HBc-expressing cells to TRAIL-induced apoptosis was associated with a significant reduction in death receptor 5 (DR5) expression. Upon transfection, HBc significantly repressed the promoter activity of the human DR5 gene. Importantly, HBc gene transfer inhibited hepatocyte death in a mouse model of HBV-induced hepatitis; and in patients with chronic hepatitis, DR5 expression in the liver was significantly reduced. These results indicate that HBc may prevent hepatocytes from TRAIL-induced apoptosis by blocking DR5 expression, which in turn contributes to the development of chronic hepatitis and HCC. They also call into question the potential side effects of HBc-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18927587     DOI: 10.1038/cdd.2008.144

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  24 in total

Review 1.  The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals.

Authors:  Ahmed Diab; Adrien Foca; Fabien Zoulim; David Durantel; Ourania Andrisani
Journal:  Antiviral Res       Date:  2017-11-26       Impact factor: 5.970

Review 2.  Apoptosis in liver carcinogenesis and chemotherapy.

Authors:  Joaquim Moreno-Càceres; Isabel Fabregat
Journal:  Hepat Oncol       Date:  2015-11-11

3.  Hepatitis B virus-triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response.

Authors:  Gu-Choul Shin; Hong Seok Kang; Ah Ram Lee; Kyun-Hwan Kim
Journal:  Autophagy       Date:  2016-10-14       Impact factor: 16.016

4.  Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis.

Authors:  Hualin Zhang; Yang Song; Huimin Yang; Zhiyan Liu; Lifen Gao; Xiaohong Liang; Chunhong Ma
Journal:  Oncogene       Date:  2018-02-16       Impact factor: 9.867

5.  Hepatitis B virus regulates apoptosis and tumorigenesis through the microRNA-15a-Smad7-transforming growth factor beta pathway.

Authors:  Ningning Liu; Tong Jiao; Yan Huang; Wenjun Liu; Zhiwei Li; Xin Ye
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

6.  Hepatitis B virus inhibits apoptosis of hepatoma cells by sponging the MicroRNA 15a/16 cluster.

Authors:  Ningning Liu; Jinfang Zhang; Tong Jiao; Zhiwei Li; Jirun Peng; Zhuqingqing Cui; Xin Ye
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

Review 7.  Dysregulation of apoptosis in hepatocellular carcinoma cells.

Authors:  Isabel Fabregat
Journal:  World J Gastroenterol       Date:  2009-02-07       Impact factor: 5.742

8.  Natural killer cell functional dichotomy: a feature of chronic viral hepatitis?

Authors:  Mario U Mondelli; Barbara Oliviero; Dalila Mele; Stefania Mantovani; Chiara Gazzabin; Stefania Varchetta
Journal:  Front Immunol       Date:  2012-11-26       Impact factor: 7.561

9.  Hepatitis B viral core protein disrupts human host gene expression by binding to promoter regions.

Authors:  Yanhai Guo; Wei Kang; Xiaoying Lei; Yongnian Li; An Xiang; Yonglan Liu; Jinrong Zhao; Ju Zhang; Zhen Yan
Journal:  BMC Genomics       Date:  2012-10-22       Impact factor: 3.969

10.  A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.

Authors:  Venturina Stagni; Simonetta Santini; Daniela Barilà
Journal:  Cancers (Basel)       Date:  2012-04-05       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.